Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Persson, Jonas ^a   Beyer, Ines ^a   Yumul, Roma ^a   Li, Zong Yi ^a   Kiem, Hans Peter ^b   Roffler, Steve ^c   Lieber, André ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LENTIVIRUS VECTOR; PROTEIN E6; PROTEIN E7; TRANSFORMING GROWTH FACTOR BETA1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TRANSGENE; TUMOR GROWTH; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; WART VIRUS; ANIMAL; C57BL MOUSE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRINAE; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

HUMAN PAPILLOMAVIRUS; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOPOIETIC STEM CELLS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LENTIVIRUS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79960303412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022303     Document Type: Article

References (43)

1. Leach DR, Krummel MF, Allison JP, (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
2. Egen JG, Kuhns MS, Allison JP, (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3: 611-618.
3. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, et al. (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60: 2444-2448.
4. van Elsas A, Hurwitz AA, Allison JP, (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355-366.
5. Agarwala SS, Ribas A, (2010) Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 33: 557-569.
6. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, et al. (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27: 1075-1081.
7. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, et al. (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23: 6043-6053.
8. Khan S, Burt DJ, Ralph C, Thistlethwaite FC, Hawkins RE, et al. (2011) Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol 138: 85-96.
9. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, et al. (2008) CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112: 1175-1183.
10. Yamaguchi T, Sakaguchi S, (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16: 115-123.
11. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, et al. (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202: 885-891.
12. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S, (2002) Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunol 3: 135-142.
13. Shimizu J, Yamazaki S, Sakaguchi M, (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a acommon basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
14. Lu H, Knutson KL, Gad E, Disis ML, (2006) The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res 66: 9754-9761.
15. Knutson KL, Almand B, Dang Y, Disis ML, (2004) Neu antigen-negative variants can be generated aftaer neu-specific antibody therapy in neu transgenic mice. Cancer Res 64: 1146-1151.
16. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, et al. (2007) Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 67: 5929-5939.
17. Griffin MD, Holman PO, Tang Q, Ashourian N, Korthauer U, et al. (2001) Development and applications of surface-linked single chain antibodies against T-cell antigens. J Immunol Methods 248: 77-90.
18. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P, (2006) A versatile tool for conditional gene expression and knockdown. Nat Methods 3: 109-116.
19. Malik P, Arumugam PI, Yee JK, Puthenveetil G, (2005) Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Ann N Y Acad Sci 1054: 238-249.
20. Li Z, Liu Y, Tuve S, Xun Y, Fan X, et al. (2009) Toward a stem cell gene therapy for breast cancer. Blood 113: 5423-5433.
21. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, et al. (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177: 1526-1533.
22. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, et al. (2006) IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177: 84-91.
23. Stone D, Liu Y, Li ZY, Strauss R, Finn EE, et al. (2008) Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. J Virol 82: 7711-7715.
24. Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, et al. (2006) Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 177: 4376-4383.
25. Quezada SA, Peggs KS, Curran MA, Allison JP, (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945.
26. Shieh SJ, Chou FC, Yu PN, Lin WC, Chang DM, et al. (2009) Transgenic expression of single-chain anti-CTLA-4 Fv on beta cells protects nonobese diabetic mice from autoimmune diabetes. J Immunol 183: 2277-2285.
27. Emery DW, Yannaki E, Tubb J, Stamatoyannopoulos G, (2000) A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A 97: 9150-9155.
28. Li CL, Emery DW, (2008) The cHS4 chromatin insulator reduces gammaretroviral vector silencing by epigenetic modifications of integrated provirus. Gene Ther 15: 49-53.
29. Strauss R, Sova P, Liu Y, Li Z-Y, Tuve S, et al. (2009) Epithelial phenotype of ovarian cancer mediates resistance to oncolytic adenoviruses. Cancer Research 15: 5115-5125.
30. Strauss R, Lieber A, (2009) Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr Opin Mol Ther 11: 513-522.
31. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F, 3rd, (2011) Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-19.
32. De Palma M, Naldini L, (2009) Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 1796: 5-10.
33. Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, et al. (2011) Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 19: 479-489.
34. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L, (2004) NKT cells: what's in a name? Nat Rev Immunol 4: 231-237.
35. Hegde S, Fox L, Wang X, Gumperz JE, (2010) Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology 130: 471-483.
36. Teige A, Bockermann R, Hasan M, Olofsson KE, Liu Y, et al. (2010) CD1d-dependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating antigen-specific Th1 responses. J Immunol 185: 345-356.
37. Terabe M, Berzofsky JA, (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101: 277-348.
38. Li MO, Flavell RA, (2008) TGF-beta: a master of all T cell trades. Cell 134: 392-404.
39. Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, et al. (2009) In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 27: 4225-4239.
40. Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, et al. (2010) Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab. Mol Ther.
41. Diao J, Zhao J, Winter E, Cattral MS, (2010) Recruitment and differentiation of conventional dendritic cell precursors in tumors. J Immunol 184: 1261-1267.
42. Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW, (2008) A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res 68: 34-43.
43. Aker M, Tubb J, Groth AC, Bukovsky AA, Bell AC, et al. (2007) Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther 18: 333-343.